Literature DB >> 30951418

Radiotherapy in the control of bleeding from primary and secondary lung tumours.

Simona Gaito1, Christopher Hughes2, David Woolf3, Ganesh Radhakrishna3.   

Abstract

This literature review clarifies the role of radiotherapy in the management of low-volume haemoptysis. Embase and Medline were interrogated, and PRISMA guidelines were then used to select relevant articles. Seventy-eight articles were considered relevant and manually reviewed. The evidence suggests that external beam radiotherapy is more effective than endobronchial brachytherapy at controlling low-volume haemoptysis. There is no evidence to recommend a combination of the two techniques. Different doses and fractionations appear equally effective, with a potential survival advantage of higher dose regimens for fitter patients. Palliative radiotherapy is effective at controlling low-volume haemoptysis. External beam radiotherapy is the first-line treatment, with endobronchial brachytherapy recommended following external beam radiotherapy failure. Choice of dose and fractionation should take into account the patient's performance status.

Entities:  

Mesh:

Year:  2019        PMID: 30951418     DOI: 10.12968/hmed.2019.80.4.211

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN: 1750-8460            Impact factor:   0.825


  2 in total

1.  Radiation treatment for refractory endometriosis: a 38-year-old female presenting with vaginal bleeding.

Authors:  Arpan V Prabhu; Michael D Schad; Alexander F Burnett; Gary D Lewis
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09

2.  Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.

Authors:  Satoshi Saito; Takanori Abe; Misaki Iino; Tomomi Aoshika; Yasuhiro Ryuno; Tomohiro Ohta; Mitsunobu Igari; Ryuta Hirai; Yu Kumazaki; Ou Yamaguchi; Kyoichi Kaira; Hiroshi Kagamu; Shin-Ei Noda; Shingo Kato
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.